Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Janux Therapeutics, Inc.JANX · Entity 4864 | Chief Corp. & Bus. Dev. Ofcr | June 02, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Janux Therapeutics, Inc.
Report date June 02, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 75,941 |
Reported balance
After 2026-06-02 transaction · row 1
1 source rowRow 1 · 2026-06-02 · Sale · Disposed 4,059 · Balance 75,941 F1: The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units. F2: The weighted average sale price for the transaction reported was $14.029 and the range of prices were between $13.96 and $14.03. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units.
F2: The weighted average sale price for the transaction reported was $14.029 and the range of prices were between $13.96 and $14.03. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2026 Filed Jun 5, 2026 00:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 4,059 | $14.03 | $56,943.71 |
DisclosureSEC source: 0002069239-26-000005 · form4-06042026_080601.xml · nonDerivative · entry 1 Doyle Janeen Noel · CIK 0002069239 · Chief Corp. & Bus. Dev. Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,941 F1 · kind: The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units. F2 · price: The weighted average sale price for the transaction reported was $14.029 and the range of prices were between $13.96 and $14.03. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| January 02, 2026 Filed Jan 3, 2026 02:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock option (right to buy) · Derivative | 126,000 | $0.00 Strike: $13.65 | $0.00 |
DisclosureSEC source: 0002069239-26-000002 · form4-01022026_090103.xml · derivative · entry 2 Doyle Janeen Noel · CIK 0002069239 · Chief Corp. & Bus. Dev. Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,000 Underlying: Common Stock · 126,000 shares Expires 2036-01-01 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2027 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
| January 02, 2026 Filed Jan 3, 2026 02:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantCommon Stock | 36,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002069239-26-000002 · form4-01022026_090103.xml · nonDerivative · entry 1 Doyle Janeen Noel · CIK 0002069239 · Chief Corp. & Bus. Dev. Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2027. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 00:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock option (right to buy) · Derivative | 154,000 | $0.00 Strike: $25.01 | $0.00 |
DisclosureSEC source: 0001415889-25-015684 · form4-06042025_080616.xml · derivative · entry 2 Doyle Janeen Noel · CIK 0002069239 · Chief Corp. & Bus. Dev. Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,000 Underlying: Common Stock · 154,000 shares Expires 2035-06-01 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on May 14, 2026 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 00:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantCommon Stock | 44,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015684 · form4-06042025_080616.xml · nonDerivative · entry 1 Doyle Janeen Noel · CIK 0002069239 · Chief Corp. & Bus. Dev. Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on June 1, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.